Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis (y

After receiving a diagnosis of actinic keratosis, the risk of developing squamous cell carcinoma over a ten year period is approximately ten per cent for a patient having an average of 7.7 actinic keratosis lesions,[8],[10],[11] and it is impossible to predict which lesions will develop into skin cancer.[12]

A study has shown that around between 40-80 per cent of squamous cell carcinoma cases may begin as actinic keratoses,[8],[13],[14] and patients with the condition are six times more likely to develop any type of skin cancer than people without it.[15]

About LEO Pharma

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.

LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally.

The company has its own sales forces in 61 countries and employs around 5,000 people worldwide.

LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation.

For more information about LEO Pharma, visit http://www.leo-pharma.com.

References

        
        1) Lebwohl M, Shumack, S et al., Long-Term Follow-up of Ingenol Mebutate Gel
          for the Treatment of Actinic Keratosis JAMA Dermatology; Article in press
        2) Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol
          mebutate gel for actinic keratosis. N Engl J Med. Mar 15 2012;366(11):1010-1019
        3) Cohen JL. Actinic keratosis treatment as a key component of preventive
          strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. Jun 2010;3(6):39-44.
        4) Ulrich M, Drecoll U, Stockfleth E. Emerging drugs for actinic keratosis.
          Expert Opin Emerg Drugs. Dec 2010;15(4):545-555.
        5) Cozzi SJ, Ogbourne SM, James C, et al. Ingenol mebutate field-directed
          treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
          J Invest Dermatol. Apr 2012;132(4):1263-1271.
        6) Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl
          angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer
          Res. Apr 15 2004;64(8):2833-2839.
        7) Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N
          Engl J Med. Apr 24 2003;348(17):1681-1691.
        8) Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of
          pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol.
          Sep 1998;37(9):677-681.
        9) Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis.
          Expert Opin Pharmacother. Dec 2009;10(18):3015-3031.
          10) Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic
          keratoses and the controversy over treatment. A patient-oriented perspective. Arch
          Dermatol. Jul 1991;127(7):1029-1031.
          11) Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma.
          J Am Acad Dermatol. Jan 2000;42(1 Pt 2):4-7.
          12) Stockfleth E. Topical management of actinic keratosis and field
          cancerisation. G Ital Dermatol Venereol. Aug 2009;144(4):459-462.
          13) Feldman SR, Fleischer AB, Jr. Progression of actinic keratosis to squamous
          cell carcinoma revisited: clinical and treatment implications. Cutis 2011;87(4):201-7.
          14) Dinehart, Nelson-Adesokan, Cockerell, Russell, Brown. Metastatic cutaneous
          squamous cell carcinoma derived from actinic keratosis. Cancer 1997; 79(5):920-3.
          15) Chen GJ, Feldman SR, Williford PM, et al. Clinical diagnosis of actinic
          keratosis identifies an elderly population at high risk of developing skin cancer.
          Dermatol Surg. Jan 2005;31(1):43-47.

    Photo:
    http://photos.prnewswire.com/prnh/201302...

CONTACT: Global Contact: Polly Lutter, Global External Relations Manager,LEO Pharma A/S, Email: polly.lutter@leo-pharma.com , +44 (0) 20 7300 6370